Interview with Robert Brown.

As soon as it was recognized that interferon-based therapy could lead to long-term viral eradication or a sustained virological response (SVR), the search was on for predictors of responses to therapy. With low response rates and the need for prolonged, costly, and difficult therapy, the primary goal was to identify patients who were unlikely to respond to treatment so that fruitless therapy could be avoided.

Treatment failure with pegylated interferon (PEG-IFN)/ribavirin (RBV) dual therapy can be due to either the persistence of hepatitis C virus (HCV) RNA throughout treatment (nonresponse) or the reappearance of the virus after the end of treatment.

The recent approval of two protease inhibitors (telaprevir and boceprevir) and the resultant increase in the sustained virological response (SVR) rate when either of these drugs is added to pegylated interferon (PEG-IFN) and ribavirin (RBV) have led to a flurry of patients with hepatitis C virus (HCV) infection seeking treatment.

Interview with Paul Martin

Chronic HCV infection in patients with Chronic Kidney Disease (CKD) undergoing hemodialysis is associated with a 57% higher risk of death compared to HCV-negative hemodialysis controls.

Interview with Sanjeev Arora.

Interview with Sanjeev Arora.

Interview with Michael R Lucey

Within the U.S. corrections system, chronic HCV infection is a major public health concern, affecting 12% to 31% of inmates, compared to approximately 1.6% of the general population.